GlassScriptPhysician profile
Urath Suresh
NPI 1629061874
$11,455.69
in general payments reported to CMS, 2019-2025
36 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $999 · 2021: $1,386 · 2022: $1,663 · 2023: $1,884 · 2024: $2,020 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,548 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,547.84 |
| Education | $182.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,591.79 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Mallinckrodt Hospital Products INC. | $1,125.46 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $1,068.84 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Vifor Pharma, INC. | $913.79 | 2019-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $662.06 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $558.14 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $556.25 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $506.44 | 2019-2025 | Ultomiris |
| Akebia Therapeutics INC | $466.15 | 2019-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $451.63 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $448.10 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $416.72 | 2023-2025 | Filspari |
| Horizon Therapeutics Plc | $376.21 | 2020-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $355.13 | 2019 | |
| Opko Pharmaceuticals, LLC | $309.48 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $298.16 | 2023-2025 | |
| Daiichi Sankyo INC. | $251.94 | 2019-2024 | Injectafer |
| Genzyme Corporation | $156.88 | 2019-2024 | |
| Shire North American Group INC | $142.60 | 2019 | |
| Glaxosmithkline, LLC. | $97.52 | 2021-2023 | Jesduvroq |
| Alnylam Pharmaceuticals INC. | $92.79 | 2019-2023 | Amvuttra |
| Ani Pharmaceuticals, INC. | $89.73 | 2023-2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $66.66 | 2023-2024 | Crysvita |
| E.R. Squibb & Sons, L.L.C. | $61.22 | 2019 | |
| Lilly USA, LLC | $49.62 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $49.53 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $46.34 | 2025 | Empaveli |
| Baxter Healthcare | $44.51 | 2019-2023 | Renal - Acute |
| Lundbeck LLC | $42.06 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.32 | 2025 | Lifevest |
| Portola Pharmaceuticals, LLC | $35.54 | 2019-2020 | |
| Ardelyx, INC. | $33.36 | 2024 | Ibsrela |
| Allergan, INC. | $21.30 | 2019 | |
| Scpharmaceuticals INC. | $17.14 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.28 | 2024 | Jardiance |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Urath Suresh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.